Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers. by Collinson, P
In this issue: Focusing on Guidelines for Laboratory Medicine and Biomarkers
Evidence and cost effectiveness requirements for recommending new biomarkers
Paul Collinson
Evidence and cost effectiveness requirements 
for recommending new biomarkers
Paul Collinson
Departments of Clinical Blood Sciences and Cardiology, St George’s Hospital and Medical School, London, UK
A R T I C L E  I N F O IS THIS TEST ‘APT’?
The literature is full of new biomarkers which are 
claimed to add to the laboratory repertoire in a 
range of conditions. The literature is often confusing 
and may be contradictory. The past 20 years is lit-
tered with publications claiming the next big thing in 
a biomarker, some of which have been implement-
ed on high throughput laboratory platforms. The 
number of novel biomarkers which have reached 
widespread clinical acceptance and implementa-
tion is relatively small. How can the laboratory com-
munity realistically assess claims for new markers? 
There is, to date, no completely defined set of crite-
ria which should be used. However, there are some 
common themes in biomarker assessment. The two 
major areas which need to be considered are evi-
dence required to assess test performance and cost 
effectiveness.
Assessment of test performance can be broadly con-
sidered under three categories, Analytical suitability, 
Plausibility and Treatment effectiveness; is the test 
APT. Analytical suitability means an assessment of the 
evidence-based analytical performance of the assay. 
This will include at least the following. Pre-analytical 
factors that will affect the test must be well under-
stood before a test can be put into routine clinical 
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practice. This will include the collection condi-
tions required, anticoagulant requirements, 
pre-analytical sample handling factors and sta-
bility in storage. A marker needs to be measur-
able in the routine clinical laboratory without 
the need for special handling conditions if it is to 
form part of the routine work-up of the patient. 
Tests requiring complex pre-analytical steps are 
tolerated by the laboratory, rather than em-
braced. Often there is no alternative; the test is 
confined to special circumstances and particu-
lar patient types which are usually rare. A test 
in the clinical routine which will be ordered in 
large numbers requires simplicity of laboratory 
handling. A recent example is the measurement 
of soluble CD40 ligand (sCD40l), a marker of 
platelet activation. Measurement of sCD40l was 
shown to be a powerful predictor of mortality 
in patients with unstable angina. In addition, 
it was shown to be a predictor of a successful 
therapeutic response to the anti-glycoprotein 
IIb/IIIa antagonist abciximab (1). These studies 
were done using serum as matrix. It was subse-
quently found that clotting releases significant 
but variable amounts of sCD40l. Studies dem-
onstrated that the release of sCD40l was criti-
cally affected by sample handling and the assay 
utilised for measurement (2).Only EDTA plasma 
could be used and values were significantly 
affected by delay in sample processing (3,4). 
Finally, it was shown that sCD40l was primar-
ily produced by in vitro platelet activation (5) 
and the first use of a commercial assay failed 
to confirm the promise of the initial publication 
(6). Analytical performance of the test needs to 
be also appropriate for clinical use. Bodies such 
as the Clinical Laboratory Standards Institute 
produce protocols for the routine assessment 
of limit of blank, limit of detection and impre-
cision profile. It is also important that these 
analytical performance measures are indepen-
dently assessed and that laboratories do not 
rely on the manufacturers’ datasheets as the 
sole source of this information. Assay impreci-
sion has a profound influence on the ability to 
define the 99th percentile and the value of the 
relative change required between two consecu-
tive measurements to be reliably different. It is 
an interesting observation that the redefinition 
of myocardial infarction (7-9) considers a 10% 
imprecision to be adequate at the 99th percen-
tile but also recommended a 20% change in 
values. Unfortunately, if the data is modelled 
it is apparent that an imprecision rather less 
than 10% is required to reliably detect a 20% 
change (http://www.westgard.com/troponin-
interpretations.htm). In addition to the ability 
to measure the biomarker with precision and 
accuracy, the analysis must be simple and have 
a rapid turnaround time. Ideally it should be 
implemented on existing laboratory equipment 
rather than requiring additional apparatus. In 
practice this means that a colorimetric or more 
likely an immunoassay for the marker is avail-
able. Population aspects of the test need to be 
understood in particular the influence of age, 
gender, ethnicity and comorbid conditions on 
the reference interval need to be considered. 
These can be quite subtle. Occult comorbid 
conditions profoundly influence the reference 
interval for cardiac troponin but can only be un-
masked by the use of rigorous patient selection 
including cardiac imaging (10,11). The need for 
appropriate patient selection for troponin refer-
ence intervals has been the subject of discus-
sion and recommendations made (12,13). 
The plausibility of the biomarker for the puta-
tive clinical role needs also to be established. 
The pathobiology of the biomarker needs to 
be understood. This means an understanding 
of the genesis of the biomarker and of the rela-
tionship of the biomarker to the medical condi-
tion of interest. A good example of this is isch-
aemia modified albumin (IMA). The concept 
of a biomarker of ischaemia is very attractive. 
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Ischaemia would be detected prior to necrosis 
(we have excellent markers for this in the car-
diac troponins) allowing intervention to abort 
the pathophysiology before irreversible cardiac 
injury occurs. The background concept of IMA 
was that the N terminus of albumin was altered 
during an ischaemic event resulting in the loss 
of the ability to bind transition metals. This was 
detectable by loss of the ability to bind cobalt, 
which could be determined by a simple colori-
metric reaction (14). Preliminary studies using 
angioplasty as a model of human myocardial 
ischaemia showed that IMA increased after bal-
loon inflation then returned rapidly to baseline 
levels, supporting the role as a biomarker of 
ischaemia (15,16). Subsequently, sequencing of 
the N terminus of IMA positive albumin showed 
that the N-terminal amino acid sequence was 
not removed (17). Physicochemical studies sug-
gested that it was the binding of free fatty ac-
ids to albumin that induced a conformational 
change that reduced transition metal bind-
ing (18). A lack of fundamental understanding 
of the biomarker was therefore apparent and 
contributed to the lack of any clinical applica-
tion (19). Plausibility also includes the clinical 
plausibility for the putative clinical role. This 
means that the biomarker must have appro-
priate sensitivity and specificity to detect the 
medical condition of interest in clinically appro-
priate populations where the test will actually 
be used in routine clinical practice. Many stud-
ies on biomarkers have evaluated them in clini-
cal trial sample banks or alternatively in highly 
selected patient groups. This does not consti-
tute an appropriate environment to evaluate 
test performance as disease prevalence is in-
appropriately high, often close to 100%. Such 
studies allow proof of concept that needs to be 
followed up by prospective evaluation in clini-
cally representative populations. Comparison of 
a sensitive with a less sensitive troponin assay 
clearly shows earlier diagnostic sensitivity (20), 
as would be expected. Early studies of the new 
high sensitivity assays showed excellent analyti-
cal performance but compared them with the 
conventional assays and included patients with 
ST segment elevation in the evaluation (21,22), 
overstating the diagnostic performance of the 
assays.
Treatment effectiveness is the final and most 
important strand to assessment. This may be 
summed up as the “so what” factor. This is 
short for the question that should be asked 
by any clinician of a test “so what do I need 
to do differently with the result of this test”. 
A new biomarker must offer either a signifi-
cant proven diagnostic efficiency or result in a 
change in treatment. Ideally it should do both. 
The change in treatment may be a decision 
to give or withhold drug or other therapeutic 
Has this marker been measured with an appropriate method and been shown to be 
additive to or replace a contemporary test?
Have there been independent studies?
Has there been a multicentre study?
Is there meta-analysis of evidence?
Has there been an RCT?
Can I measure it in the routine lab without additional equipment and staff?
Table 1 Key questions for evaluating the evidence base for clinical use
Page 185
eJIFCC2015Vol26No3pp183-189
Paul Collinson
Evidence and cost effectiveness requirements for recommending new biomarkers
intervention or to change the management 
pathway such as more prompt hospital dis-
charge or admission to an appropriate level of 
clinical care. The questions which should pass 
through the laboratory practitioners’ mind are 
shown in Table 1 below.
An example of a randomised controlled tri-
al of the diagnostic test is the Randomised 
Assessment of Treatment using Panel Assays 
of Cardiac markers (RATPAC) (23). This was a 
pragmatic randomised controlled trial which 
compared two treatment strategies, conven-
tional management with measurement on ad-
mission and at 90 minutes of a panel of cardiac 
troponin I, creatine kinase MB and myoglobin 
by point of care testing. The outcome measure 
was a proportion of patients discharged or a 
decision to discharge within four hours of at-
tendance with no adverse events during the 
following three months. Randomisation to the 
point of care arm of the study was reflected in 
increased successful discharge and no change 
in the frequency of adverse events. There was 
increased use of coronary care in the point of 
care arm. One of the most interesting aspects 
of this study was the significant differences 
between the six different sites with only two 
showing very large differences in length of stay 
in those randomised to the point of care arm 
(24). It highlights the importance of process 
within the utilisation of test results. Simple 
provision of rapid results will be ineffective un-
less it is accompanied by treatment decision.
IS THIS TEST COST EFFECTIVE?
Cost effectiveness considers the impact on 
health care resources utilisation and how we as-
sess it. Cost effectiveness can be considered un-
der four categories as shown in Table 2 below. It 
should be noted however that the terminology 
is often mixed.
Cost minimisation analysis is the most straight-
forward. It assumes that the consequences of 
the two interventions being compared are iden-
tical so the analysis reduces to the comparison 
of costs alone. An example would be the diagno-
sis of acute myocardial infarction using cardiac 
troponin (cTn) compared to the measurement 
of creatine kinase MB isoenzyme (CK-MB). If 
the assumption is that CK-MB costs 20 currency 
units (CU) and cTn 30 CU then a protocol involv-
ing three hourly CK-MB measurements for 12 
hours (total cost 80 CU) will be more expensive 
than a protocol measuring cTn on admission 
and 12 hours from admission (total cost 60 CU). 
In cost effectiveness analysis differences can be 
expressed in terms of changes in one main pa-
rameter. The differences in costs are related to 
the main differences in events. An example of 
this type of analysis is the use of measurement 
of B type natriuretic peptide (BNP) in patients 
with suspected chronic heart failure. The basic 
Type Measurement and valuation of consequences
Cost minimisation analysis No measurement. Consequences assumed or shown to 
be equivalent.
Cost effectiveness analysis Natural units (Life years gained)
Cost utility analysis Health state preference values (quality adjusted life 
years gained)
Cost benefit analysis Monetary gains
Table 2 Cost effectiveness categories
Page 186
eJIFCC2015Vol26No3pp183-189
Paul Collinson
Evidence and cost effectiveness requirements for recommending new biomarkers
premise is that two pathways are compared: di-
rect referral for hospital assessment of patients 
with suspected heart failure and referral only 
of those with an elevated BNP. A simple analy-
sis compares costs at the pathway level where 
the costs of echocardiography on all patients is 
compared with the combined cost of BNP mea-
surement followed by echocardiography only in 
the those with BNP levels above a certain des-
ignated threshold. This is effectively a cost mini-
misation analysis and shows that the BNP based 
pathway is cheaper (25). A more sophisticated 
approach utilising a sequential testing strategy 
modelled on individual patient data meta-anal-
ysis was performed as part of a health technol-
ogy assessment informing the National Institute 
of Clinical and health Excellence (NICE) guide-
lines on BNP testing. This modelling produced 
very similar results to the cost minimisation 
model. Cost effectiveness was driven by the 
prior probability of disease and favoured BNP 
measurement as the first test (as in strategy dis-
cussed above) unless the probability of heart 
failure was very high (26). Cost utility analysis 
typically utilises the quality adjusted life year 
(QALY). A QALY takes into account longevity and 
quality-of-life. The number of QALYs accrued by 
a patient is estimated by multiplying the years 
of survival by quality-of-life measured on a scale 
from zero (equivalent to death) to 1 (perfect 
health). States of health below zero are pos-
sible for a health state considered worse than 
death. QALYs have the advantage of allowing 
comparison between any healthcare interven-
tion that can influence survival or quality-of-life. 
Analysis is based on willingness to pay (cost per 
QALY) with a typical threshold of £20,000 in the 
UK. An example would be comparison of the 
cost effectiveness of measurement of high sen-
sitivity troponin on admission versus conven-
tional troponin management at 10 hours (27). 
Such a study shows that high sensitivity tropo-
nin measurement on admission is superior to 
conventional troponin measurement and that 
measurement on admission and at three hours 
is the most sensitive approach. Measurement 
of conventional troponin at 10 hours is only cost 
effective if an immediate decision to discharge 
is made, highlighting again the importance of 
process in the application of laboratory testing. 
One problem with cost effectiveness analysis in 
diagnostics is that the data is often inadequate 
or even non-existent. Modelling approaches are 
typically used but the accuracy of the cost mod-
elling is often challenging though mitigated by 
sensitivity analysis (changing the model param-
eter and looking at the impact, a large change 
suggests that the modelling is not robust). Very 
small differences in QALY’s may be present.
A systematic attempt to evaluate the evidence 
for diagnostics including laboratory testing is 
used by the Diagnostics Assessment Committee 
of NICE. They utilise a systematic evidence-based 
review followed by cost economic modelling. 
The recommendations and their evidence base 
can be found on the NICE website (www.nice.
org.uk) and in the publications of the UK health 
technology assessment programme. These are 
all available online. Examples are the recent 
recommendations for the use of faecal calpro-
tectin (www.nice.org.uk/guidance/dg11) and 
the accompanying evidence report (28).
CONCLUSIONS
In conclusion, assessment of test suitability is 
a combination of the traditional laboratory at-
tributes of the analytical performance of the 
test but combined with other features. The 
underlying scientific validity of the test needs 
to be understood and the diagnostic utility 
demonstrated in appropriate populations, to 
show the test is plausible. Finally, the test re-
sult must produce a treatment change. All of 
these, Analytical, Plausibility, Treatment will 
make a test APT. But an APT test clinically also 
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needs to be cost effective. Conversely, unless a 
test has been shown to be APT, the probability 
of demonstrating cost effectiveness is small. 
The challenge for the laboratory is to work to-
gether with clinicians to develop test evalua-
tion strategies that will allow demonstration of 
all the attributes to show that the test is both 
APT and cost effective.
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